Abiopharma

Castle Biosciences - Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’si31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB